Physician profile
Mark Weissman
NPI 1003875691
$891.07
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $163 · 2021: $69.99 · 2022: $272.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $201.04 | 2019-2022 | |
| Abbvie INC. | $125.60 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $80.43 | 2019-2020 | |
| Novo Nordisk INC | $69.88 | 2019-2020 | |
| Scynexis, INC. | $62.97 | 2022 | |
| Amgen INC. | $52.45 | 2019-2020 | |
| Therapeuticsmd, INC. | $44.73 | 2020-2022 | |
| Coopersurgical, INC. | $39.21 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $27.87 | 2019-2020 | |
| Hologic Sales and Service, LLC | $25.81 | 2020 | |
| Evofem Biosciences, INC. | $24.91 | 2021 | |
| Gilead Sciences, INC. | $24.86 | 2022 | |
| Daiichi Sankyo INC. | $20.47 | 2019 | |
| Mylan Pharmaceuticals INC. | $19.75 | 2022 | |
| Duchesnay USA Incorporated | $16.53 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $15.09 | 2022 | |
| Organon LLC | $14.97 | 2021 | |
| Ferring Pharmaceuticals INC. | $13.59 | 2019 | |
| Covidien Lp | $10.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Weissman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.